TRANSCRIPT — 00:14:00
Questions, answered carefully.
Fifteen of the most common questions readers bring here, with answers drawn from the published literature and the FDA, ClinicalTrials.gov, and WADA records.
Can a doctor prescribe CJC-1295?
A U.S. physician can write a prescription for any compound. The harder question is whether a pharmacy can lawfully fill it. For an unapproved compound like CJC-1295, the only legal dispensing route is pharmacy compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act, and 503A has three statutory criteria — a USP/NF monograph, status as a component of an FDA-approved drug, or inclusion on the FDA 503A bulks list. CJC-1295 satisfies none of these as of 2026 [20]. So while a doctor can write a script, no traditional state-licensed compounding pharmacy operating in 503A compliance has a lawful path to fill it.
Is CJC-1295 available by prescription anywhere in the U.S.?
Not as a conventionally manufactured FDA-approved product. CJC-1295 does not appear in the FDA Drugs@FDA database; no New Drug Application has ever been submitted, and the original Phase 2 program was terminated in October 2006 after a participant death [8][14]. Some wellness-clinic networks and compounding pharmacies have historically supplied the compound in regulatory gray zones, but that practice is not consistent with the current 503A statutory criteria [20]. The February 27, 2026 HHS announcement signaled intent to change this — see the dedicated question below — but as of May 2026 no Federal Register rule had been issued.
What is the current FDA prescribing status of CJC-1295?
Unapproved for any human indication [14]. CJC-1295 was placed in interim 503A Category 2 in 2023, removed from Category 2 effective September 27, 2024 after the original nominators withdrew their nominations, and the entire Category 1/2/3 framework was closed to new nominations on January 7, 2025 [16][18]. The compound is therefore not formally banned by categorization, but it also does not appear in Category 1 (eligible for compounding). It sits in a kind of regulatory open file — failing the 503A criteria substantively, while the framework that once categorized it has been retired procedurally.
Why can't a compounding pharmacy just fill a CJC-1295 script?
Because the statute — Section 503A of the FD&C Act — requires bulk drug substances used in traditional compounding to satisfy at least one of three criteria, and CJC-1295 satisfies none [20]. First, there is no USP/NF monograph for CJC-1295. Second, CJC-1295 is not a component of any FDA-approved drug. Third, CJC-1295 is not on the FDA 503A bulks list — it was briefly in Category 2 (do-not-compound), was removed from that category in September 2024 after nominator withdrawal, and never made it into Category 1 [16]. All three pathways are closed. A prescription, on its own, does not authorize compounding.
What did the 2024 FDA PCAC meetings decide?
The Pharmacy Compounding Advisory Committee met twice in 2024 on the GH-secretagogue peptide class. At the October 29, 2024 meeting, FDA briefing materials (Docket FDA-2024-N-4777) reviewed CJC-1295 — free base, acetate, with-DAC free base, DAC acetate, and DAC trifluoroacetate — and the agency's pre-meeting position was that the substance did not meet 503A bulks-list criteria. Cited concerns included limited human safety data, immunogenicity risk from peptide impurities, theoretical cardiac risk referencing the 2006 trial fatality, and the absence of a USP monograph [15]. At the December 4, 2024 follow-up, the committee revisited the class as a whole, consolidated public comment and manufacturer evidence, and reiterated that the available evidence did not support routine 503A compounding access [17].
What happened with the September 2024 Category 2 removal?
On September 20, 2024 FDA announced the removal of CJC-1295 (across five salt and DAC variants) from Category 2 of the interim 503A bulks list, effective September 27, 2024 [16]. The removal followed the withdrawal of the original 503A nominations by the parties that had submitted them. Removal from Category 2 is not the same as placement into Category 1. The substance returned to a "no listing" state — not formally banned by category, but not eligible for routine compounding either, because it still fails all three 503A statutory criteria [20]. The change was a procedural step, not a substantive reclassification.
Does the February 2026 HHS announcement mean I can get a prescription now?
Not as of May 2026, no. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced on the Joe Rogan Experience #2461 an intent to reclassify approximately fourteen peptides — explicitly including CJC-1295 — toward a Category 1 framework, with a stated effective date of April 23, 2026 and a planned PCAC review at the July 23-24, 2026 meeting [22]. A public statement of intent is not the same as a Federal Register rule. As of May 2026 the formal regulatory action had not been published, which means the on-the-ground prescribing status is technically unchanged. Compounding pharmacies operating in 503A compliance still cannot lawfully prepare the compound under current criteria. Whether the announcement matures into a binding rule, and on what timeline, is an open question.
What is the difference between CJC-1295 with DAC and without DAC?
These are pharmacokinetically distinct molecules that share a backbone. CJC-1295 with DAC carries a C-terminal maleimidopropionic acid group that covalently bonds to the free thiol on Cys34 of circulating serum albumin, shielding the peptide from clearance and producing a plasma half-life of roughly 5.8 to 8.1 days [3]. CJC-1295 without DAC — more correctly called modified GRF(1-29) — is just the substituted backbone without the maleimide tether, with a plasma half-life of approximately 30 minutes [9]. Both share the same four amino-acid substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) that resist enzymatic degradation. Research-chemical marketing routinely conflates the two; the published pharmacology does not.
What is the half-life of CJC-1295?
For the DAC variant, mean plasma half-life across the Teichman 2006 dose cohorts was 5.8 to 8.1 days in healthy adults [3]. That multi-day persistence is the central pharmacokinetic feature of the molecule and is attributable to covalent albumin tethering. For the non-DAC backbone (modified GRF 1-29), plasma half-life is approximately 30 minutes, compared with about seven minutes for native GHRH — a four-fold extension achieved by the four amino-acid substitutions alone [9]. The remaining roughly 300-fold extension from 30 minutes to 5.8-8.1 days is entirely the DAC tether's contribution.
What does the published human research actually show?
Teichman et al. (2006) is the only peer-reviewed Phase 1 paper. At single subcutaneous doses of 30, 60, 125, and 250 μg/kg in healthy adults, mean plasma GH rose two- to ten-fold above baseline and stayed elevated for at least six days; mean IGF-1 rose 1.5- to three-fold and stayed elevated for nine to eleven days. Multi-dose cohorts sustained IGF-1 elevation out to 28 days [2]. Ionescu and Frohman (2006) showed that GH secretion remained pulsatile under continuous CJC-1295 stimulation, with trough GH rising approximately 7.5-fold [5]. A 2009 proteomic substudy identified five serum-protein biomarkers of GH/IGF-1 axis activation [6]. That is the entire peer-reviewed human dataset.
What were the doses used in the only published CJC-1295 Phase 1 trial?
Four single-injection dose cohorts: 30, 60, 125, and 250 μg/kg subcutaneous [2]. Each cohort received a single subcutaneous administration; PK/PD measurements were collected over the days that followed. A companion multi-dose substudy administered weekly or biweekly injections at the same dose levels for 28 to 49 days. Participants were healthy adults aged 21 to 61. No subsequent Phase 1 trial at a different dose range has been published.
Why was the Phase 2 trial halted?
The Phase 2 trial in HIV-associated visceral adiposity (NCT00267527, n=192) was terminated in October 2006 after a participant death from an acute coronary event approximately two hours after the eleventh weekly dose [8]. An independent review judged the death unrelated to study drug — the participant had pre-existing undiagnosed coronary artery disease — but the sponsor (ConjuChem) halted the program and never restarted it. Primary efficacy endpoint data were not published. The unresolved cardiac signal has been cited in subsequent FDA briefing materials as a contributing concern [15], even with the external adjudication of "not related."
What is CJC-1295's status under WADA anti-doping rules?
Prohibited at all times — both in- and out-of-competition — under Section S2 of the World Anti-Doping Code (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) [13]. Use by any athlete subject to WADA testing constitutes an Anti-Doping Rule Violation. Detection methods using nano-LC Orbitrap mass spectrometry are validated for routine urine doping-control analysis at sub-ng/mL limits [10]. The compound was identified in seized illicit pharmaceutical preparations as far back as 2010 [7].
Is the related peptide tesamorelin a prescription drug?
Yes. Tesamorelin is an FDA-approved GHRH analog indicated for the reduction of excess abdominal fat in HIV patients with lipodystrophy [19]. It is supplied as a lyophilized powder for daily subcutaneous reconstitution at a 2 mg dose. The pivotal randomized clinical trial reported a 15-20% reduction in visceral adipose tissue over 26 weeks of daily dosing [19]. Tesamorelin is the closest FDA-approved relative of CJC-1295 and is the example of what an actual regulated, prescribable GHRH-analog product looks like — including a labeled indication, a labeled dose, a manufacturer-supplied formulation, and a pharmacy distribution chain.
Where do current users actually obtain CJC-1295?
Outside any FDA-approved prescription pathway. A 2016 netnographic analysis of nine online bodybuilding forums and 23 discussion threads documented self-reported acquisition through research-chemical channels and gray-market wellness clinics, with reported uses spanning weight loss, muscle gain, sleep quality, and recovery [21]. The 2010 seizure of an illicit pharmaceutical preparation identified as CJC-1295 by mass spectrometry illustrates the parallel-market history [7]. Identity and purity in non-pharmaceutical channels are not assured; without a regulated supply chain, there is no chain-of-custody guarantee that any given vial contains the labeled compound at the labeled potency.